Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: Drug-discovery strategies

References

• Abadji V, Lin S, Taha G, Griffin G, Stevenson LA, Pertwee RG, et al. (R)-methanandamide: A chiral novel anandamide possessing higher potency and metabolic stability. Journal of Medicinal Chemistry 1994; 37: 1889–1893
   PubMed Web of Science ®Google Scholar
• Ahn K, McKinney MK, Cravatt BF. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chemical Reviews 2008; 108: 1687–1707
   PubMed Web of Science ®Google Scholar
• Alexander JP, Cravatt BF. Mechanism of carbamate inactivation of FAAH: Implications for the design of covalent inhibitors and in vivo functional probes for enzymes. Chemistry & Biology 2005; 12: 1179–1187
   PubMed Web of Science ®Google Scholar
• Alexander JP, Cravatt BF. The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. Journal of the American Chemical Society 2006; 128: 9699–9704
   PubMed Web of Science ®Google Scholar
• Anderson BJ. Paracetamol (Acetaminophen): Mechanisms of action. Paediatric Anesthesiology 2008; 18: 915–921
   PubMed Web of Science ®Google Scholar
• Ashton JC, Glass M. The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Current Neuropharmacology 2007; 5: 73–80
   PubMed Web of Science ®Google Scholar
• Ashton JC, Wright JL, McPartland JM, Tyndall DA. Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. Current Medicinal Chemistry 2008; 15: 1428–1443
   PubMed Web of Science ®Google Scholar
• Bachur NR, Masek K, Melmon KL, Udenfriend S. Fatty acid amides of ethanolamine in mammalian tissues. Journal of Biological Chemistry 1965; 240: 1019–1024
   PubMedGoogle Scholar
• Bambico FR, Katz N, Debonnel G, Gobbi G. Cannabinoids elicit antidepressant-like behavior and activate serotoneric neurons through the medial prefrontal cortex. Journal of Neuroscience 2007; 27: 11700–11711
   PubMed Web of Science ®Google Scholar
• Bell MR, D’Ambra TE, Kumar V, Eissenstat MA, Herrmann JL, Jr, Wetzel JR, et al. Antinociceptive (aminoalkyl)indoles. Journal of Medicinal Chemistry 1991; 34: 1099–1110
   PubMed Web of Science ®Google Scholar
• Bergman J, Delatte MS, Paronis CA, Vemuri K, Thakur GA, Makriyannis A. Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties. Physiology & Behavior 2008; 93: 666–670
   PubMed Web of Science ®Google Scholar
• Bortolato M, Campolongo P, Mangieri RA, Scattoni ML, Frau R, Trezza V, et al. Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology 2006; 31: 2652–2659
   PubMed Web of Science ®Google Scholar
• Bouaboula M, Dussossoy D, Casellas P. Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses. Journal of Biological Chemistry 1999; 274: 29307–29405
   Google Scholar
• Canals M, Milligan G. Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed mu opioid receptors. Journal of Biological Chemistry 2008; 283: 11424–11434
   PubMed Web of Science ®Google Scholar
• Carbonare MD, Del Giudice E, Stecca A, Colavito D, Fabris M, D’Arrigo A, et al. A saturated N-acylethanolamine other than N-palmitoyl ethanolamine with anti-inflammatory properties: A neglected story. Journal of Neuroendocrinology 2008; 20(Suppl.1)26–34
   PubMedGoogle Scholar
• Charalambous A, Lin S, Marciniak G, Banijamali A, Friend FL, Compton DR, et al. Pharmacological evaluation of halogenated Δ8-THC analogs. Pharmacology, Biochemistry, and Behavior 1991; 40: 509–512
   PubMedGoogle Scholar
• Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL. Appetite supression and weight loss after the cannabinoid antagonist SR 141716. Life Sciences 1998; 63: PL113–PL117
   PubMed Web of Science ®Google Scholar
• Deutsch DG, Lin S, Hill WA, Morse KL, Salehani D, Arreaza G, et al. Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Biochemical and Biophysical Research Communications 1997; 231: 217–221
   PubMed Web of Science ®Google Scholar
• Dickason-Chesterfield AK, Kidd SR, Moore SA, Schaus JM, Liu B, Nomikos GG, et al. Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors. Cellular and Molecular Neurobiology 2006; 26: 407–423
   PubMedGoogle Scholar
• Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nature Reviews Drug Discovery 2004; 3: 771–784
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Bisogno T, De Petrocellis L, Brandi I, Jefferson RG, Winckler RL, et al. Highly selective CB1 cannabinoid receptor ligands and novel CB1/VR1 vanilloid receptor ‘hybrid’ ligands. Biochemmical and Biophysical Research Communications 2001; 281: 444–451
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Current Opinion in Lipidology 2007; 18: 129–140
   PubMed Web of Science ®Google Scholar
• Drago F. Endocannabinoids and psycopathology: The therapy inside. Pharmacological Research 2007; 56: 357–359
   PubMedGoogle Scholar
• Ehrhart J, Obregon D, Mori T, Hou H, Sun N, Bai Y, et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. Neuroinflammation 2005; 2: 29
   PubMed Web of Science ®Google Scholar
• Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): Effects on anandamide and oleoylethanolamide deactivation. Journal of Pharmacology and Experimental Therapeutics 2005; 313: 352–358
   PubMed Web of Science ®Google Scholar
• Fowler CJ, Tiger G, Ligresti A, López-Rodríguez ML, Di Marzo V. Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis–a difficult issue to handle. European Journal of Pharmacology 2004; 492: 1–11
   PubMedGoogle Scholar
• Fulmer T. Not cutting the fat. BioCentury 2008; 16: A9–A10
   Google Scholar
• Gaetani S, Cuomo V, Piomelli D. Anandamide hydrolysis: A new target for anti-anxiety drugs. Trends in Molecular Medicine 2003; 9: 474–478
   PubMedGoogle Scholar
• Gatley SJ, Lan R, Pyatt B, Gifford AN, Volkow ND, Makriyannis A. Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sciences 1997; 61: L191–L197
   Google Scholar
• Gatley SJ, Lan R, Volkow ND, Pappas N, King P, Wong CT, et al. Imaging the brain marijuana receptor: Development of a radioligand that binds to cannabinoid CB1 receptors in vivo. Journal of Neurochemistry 1998; 70: 417–423
   PubMed Web of Science ®Google Scholar
• Gifford A, Bruneus M, Lin S, Goutopoulos A, Makriyannis A, Zvolkow ND, et al. Potentiation of the action of anandamide on hippocampal slices by the fatty acid amide hydrolase inhibitor, palmitylsulphonyl fluoride (AM 374). European Journal of Pharmacology 1999; 383: 9–14
   PubMed Web of Science ®Google Scholar
• Giuffrida A, Rodriguez de Fonseca F, Nava F, Loubet-Lescoulié P, Piomelli D. Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404. European Journal of Pharmacology 2000; 408: 161–168
   PubMed Web of Science ®Google Scholar
• Gonzalez R. Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance. Neuropsychology Reviews 2007; 17: 347–361
   PubMed Web of Science ®Google Scholar
• Hanuŝ L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, et al. 2-Arachidonoyl glyceryl ether, an endogeous agonist of the cannabinoid CB1 receptor. Proceedings of the National Academy of Sciences of the USA 2001; 98: 3662–3665
   PubMed Web of Science ®Google Scholar
• Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Coata BR, et al. Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences of the USA 1990; 87: 1932–1936
   PubMed Web of Science ®Google Scholar
• Hillard CJ, Manna S, Greenberg MJ, Dicamelli R, Ross RA, Stevenson LA, et al. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). Journal of Pharmacology and Experimental Therapeutics 1999; 289: 1427–1433
   PubMed Web of Science ®Google Scholar
• Hodge J, Bow JP, Plyler KS, Vemuri VK, Wisniecki A, Salamone JD, et al. The cannabinoid CB1 receptor inverse agonist AM 251 and antagonist AM 4113 produce similar effects on the behavioral satiety sequence in rats. Behavioral Brain Research 2008; 193: 298–305
   PubMed Web of Science ®Google Scholar
• Hurst DP, Lynch DL, Barnett-Norris J, Hyatt SM, Seltzman HH, Zhong M, et al. N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Molecular Pharmacology 2002; 62: 1274–1287
   PubMed Web of Science ®Google Scholar
• Ibrahim MM, Deng, H. Zvonok A, Cockayne DA, Kwan J, Mata HP, et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS. Proceedings of the National Academy of Sciences of the USA 2003; 100: 10529–10533
   PubMed Web of Science ®Google Scholar
• Jagerovic N, Fernandez-Fernandez C, Goya P. CB1 cannabinoid antagonists: Structure-activity relationships and potential therapeutic applications. Current Topics in Medicinal Chemistry 2008; 8: 205–230
   PubMed Web of Science ®Google Scholar
• Janero DR, Makriyannis A. Targeted modulators of the endogenous cannabinoid system: future medications to treat addiction disorders and obesity. Current Psychiatry Reports 2007; 9: 365–373
   PubMedGoogle Scholar
• Jayamanne A, Greenwood R, Mitchell VA, Asian S, Piomelli D, Vaughan CW. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. British Journal of Pharmacology 2006; 147: 281–288
   PubMed Web of Science ®Google Scholar
• Karanian DA, Karim SL, Wood JT, Williams JS, Lin S, Makriyannis A, et al. Endocannnabinoid enhancement protects against kainic acid-induced seizures and associated brain damage. Journal of Pharmacology and Experimental Therapeutics 2007; 322: 1059–1066
   PubMed Web of Science ®Google Scholar
• Khanapure SP, Garvey DS, Janero DR, Letts LG. Eicosanoids in inflammation: Biosynthesis, pharmacology, and therapeutic frontiers. Current Topics in Medicinal Chemistry 2007; 7: 311–340
   PubMed Web of Science ®Google Scholar
• Khanolkar AD, Lu D, Ibrahim M, Duclos RI, Jr, Thakur GA, Malan TP, Jr, et al. Cannabilactones: A novel class of CB2 selective agonists with peripheral analgesic activity. Journal of Medicinal Chemistry 2007; 50: 6493–6550
   PubMed Web of Science ®Google Scholar
• Kozak KR, Marrnett LJ. Oxidative metabolism of endocannabinoids. Prostaglandins Leukotrienes Essential Fatty Acids 2002; 66: 211–220
   PubMed Web of Science ®Google Scholar
• Kunos G, Osei-Hyiaman D, Bátaki S, Sharkey KA, Makriyannis A. Should peripheral CB1 cannabinoid receptors be selectively targeted for therapeurtic gain?. Trends in Pharmacological Sciences 2008; 30: 1–7
   PubMedGoogle Scholar
• Labar G, Michaux C. Fatty acid amide hydrolase: From characterization to therapeutics. Chemistry & Biodiversity 2007; 4: 1882–1902
   PubMed Web of Science ®Google Scholar
• Lambert DM, Di Marzo V. The palmitoylethanolamide and oleamide enigmas: Are these two fatty acid amides cannabimimetic?. Current Medicinal Chemistry 1999; 6: 757–773
   PubMed Web of Science ®Google Scholar
• Lambert DM, DiPaolo FG, Sonveaux P, Kanyonyo M, Govaerts SJ, Hermans E, et al. Analogs and homologs of n-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors. Biochimica et Biophysica Acta 1999; 1440: 266–274
   PubMed Web of Science ®Google Scholar
• Lambert DM, Vandevoorde S, Jonsson KO, Fowler CJ. The palmitoylethanolamide family: A new class of anti-inflammatory agents?. Current Medicinal Chemistry 2002; 9: 663–674
   PubMed Web of Science ®Google Scholar
• Lange JHM, Kruse CG. Cannabinoid CB1 receptor antagonists in therapeutic and structural perspectives. Chemical Record 2008; 8: 156–168
   PubMedGoogle Scholar
• Lastres-Becker I, de Miguel R, De Petrocellis L, Makriyannis A, Di Marzo V, Fernández-Ruiz J. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. Journal of Neurochemistry 2003; 84: 1097–1109
   PubMed Web of Science ®Google Scholar
• Leweke FM, Koethe D. Cannabis and psychiatric disorders: It is not only addiction. Addiction Biology 2008; 13: 264–275
   PubMed Web of Science ®Google Scholar
• Lin S, Khanolkar AD, Fan P, Goutopoulos A, Qin C, Papahadjis D, et al. Novel analogues of arachidonoylethanolamide (anandamide): Affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. Journal of Medicinal Chemistry 1998; 41: 5353–5361
   PubMed Web of Science ®Google Scholar
• Lombard C, Nagarkatti M, Nagarkatti P. CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: Potential role for CB2-selective ligands as immunosuppressive agents. Clinical Immunology 2007; 122: 259–270
   PubMed Web of Science ®Google Scholar
• Lu D, Meng Z, Thakur GA, Fan P, Steed J, Tartal CL, et al. Adamantyl cannabinoids: A novel class of cannabinergic ligands. Journal of Medicinal Chemistry 2005; 48: 4576–4585
   PubMed Web of Science ®Google Scholar
• Luk T, Jin W, Zvonok A, Lu D, Lin X-Z, Chavkin C, et al. Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist. British Journal of Pharmacology 2004; 142: 495–500
   PubMed Web of Science ®Google Scholar
• Mackie K, Stella N. Cannabinoid receptors and endocannabinoids: Evidence for new players. American Association of Pharmaceutical Scientists Journal 2006; 8: E298–E306
   Google Scholar
• Maione S, Morera E, Marabese I, Ligresti A, Luongo L, Ortar G, et al. Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: Cannabinoid and non-cannabinoid receptor-mediated mechanisms. British Journal of Pharmacology 2008; 155: 775–782
   PubMedGoogle Scholar
• Makriyannis A, Rapaka R. The molecular basis of cannabinoid activity. Life Sciences 1990; 47: 2173–2184
   PubMedGoogle Scholar
• Malan TP, Jr, Ibrahim MM, Deng H, Liu Q, Mata HP, Vanderah T, et al. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 2001; 93: 239–245
   PubMed Web of Science ®Google Scholar
• Malan TP, Jr, Ibrahim MM, Lai J, Vanderah TW, Makriyannis A, Porreca F. CB2 cannabinoid receptor agonists: Pain relief without psychoactive effects?. Current Opinion in Pharmacology 2003; 3: 62–67
   PubMed Web of Science ®Google Scholar
• Marriott K-SC, Huffman JW. Recent advances in the development of selective ligands for the cannabinoid CB2 receptor. Current Topics in Medicinal Chemistry 2008; 8: 187–204
   PubMed Web of Science ®Google Scholar
• McPartland JM, Glass M, Pertwee RG. Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: Interspecies differences. British Journal of Pharmacology 2007; 152: 583–593
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology 1995; 50: 83–90
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Feigenbaum JJ, Lander N, Segal M, Järbe TU, Hiltunen AJ, et al. Enantiomeric cannabinoids: Stereopsecificity of psychotropic activity. Experientia 1988; 44: 762–774
   PubMedGoogle Scholar
• Mechoulam R, Peters M, Murillo-Rodriguez E, Hanuš LO. Cannabidiol—recent advances. Chemistry & Biodiversity 2007; 4: 1678–1692
   PubMed Web of Science ®Google Scholar
• Merck. Research and Development News. Merck discontinues development of investigational medicine taranabant for obesity 2008, Available at: http://www.merck.com/newsroom/press_releases/research_and_development/2008_1002.html (accessed October 2008)
   Google Scholar
• Moriera FA, Lutz B. The endocannabinoid system: Emotion, learning and addiction. Addiction Biology 2008; 13: 196–212
   PubMedGoogle Scholar
• Muccioli GG. Blocking the cannabinoid receptors: Drug candidates and therapeutic promises. Chemistry & Biodiversity 2007; 4: 1805–1827
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Adams M, Whiteaker K, Daza A, Kage K, Cassar S, et al. Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors. European Journal of Pharmacology 2004; 505: 1–9
   PubMed Web of Science ®Google Scholar
• Ortar G, Bisogno T, Ligresti A, Morera E, Nalli M, Di Marzo V. Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. Journal of Medicinal Chemistry 2008; 51: 6970–6979
   PubMed Web of Science ®Google Scholar
• Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, Jeong W, et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. Journal of Clinical Investigation 2008; 118: 3160–3169
   PubMed Web of Science ®Google Scholar
• Pertwee RG. The therapeutic potential of drugs that target cannabinoid receptors or modulate tissue levels or actions of endocannabinoids. American Association of Pharmaceutical Scientists Journal 2005; 7: E625–E654
   Google Scholar
• Pertwee RG. GPR55: A new member of the cannabinoid receptor clan?. British Journal of Pharmacology 2007; 152: 984–986
   PubMed Web of Science ®Google Scholar
• Pertwee R. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology 2008; 153: 199–215
   PubMed Web of Science ®Google Scholar
• Pertwee R, Griffin G, Fernando S, Li X, Hill A, Makriyannis A. AM630, a competitive cannabinoid antagonist. Life Sciences 1995; 56: 1949–1955
   PubMed Web of Science ®Google Scholar
• Pfizer. Pfizer discontinues development program for its phase 3 obesity compound (CP-945-598) 2008, Available at: http://mediaroom.pfizer.com/news/Pfizer/20081105006339/en (accessed November 2008)
   Google Scholar
• Rawls SM, Ding Z, Cowan A. Role of TRPV1 and cannabinoid CB1 receptors in AM 404-evoked hypothermia in rats. Pharmacology, Biochemistry, and Behavior 2006; 83: 508–516
   PubMed Web of Science ®Google Scholar
• Re G, Barbero R, Miolo A, Di Marzo V. Palmitoylethanolamide, endocannabinoids, and related cannabimimetic compounds in protection against tissue inflammation and pain: Potential use in companion animals. Veterinary Journal 2007; 173: 21–30
   PubMed Web of Science ®Google Scholar
• Reggio PH, Basu-Dutt S, Barnett-Norris J, Castro M, Hurst DP, Seltzman HH, et al. The bioactive conformation of aminoalkylindoles at the cannabinoid CB1 and CB2 receptors: Insignts gained from (E)- and (Z)-naphthylidene indenes. Journal of Medicinal Chemistry 1998; 41: 5177–5187
   PubMedGoogle Scholar
• Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. Federation of European Biochemical Societies Letters 1994; 350: 240–244
   PubMed Web of Science ®Google Scholar
• Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, et al. SR144528, the first potent and selective antagonist of the CB2 receptor. Journal of Pharmacology and Experimental Therapeutics 1998; 284: 644–650
   PubMed Web of Science ®Google Scholar
• Romero-Sandoval A, Nutile-McMenemy N, DeLeo JA. Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury. Anesthesiology 2008; 108: 722–734
   PubMed Web of Science ®Google Scholar
• Ross RA. Allosterism and cannabinoid CB1 receptors: The shape of things to come. Trends in Pharmacological Sciences 2007; 28: 567–572
   PubMedGoogle Scholar
• Rumsfeld JS, Nallamothu BK. The hope and fear of rimonabant. Journal of the American Medical Association 2008; 299: 1601–1602
   PubMed Web of Science ®Google Scholar
• Saario SM, Salo OM, Nevalainen T, Poso A, Laitinen JT, Järvinen T, et al. Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes. Chemistry & Biology 2005; 12: 649–656
   PubMedGoogle Scholar
• Salamone JD, McLaughlin PJ, Sink K, Makriyannis A, Parker LA. Cannabinoid CB1 receptor inverse agonists and neutral antagonists: Effects on food intake, food-reinforced behavior and food aversions. Physiology & Behavior 2007; 91: 383–388
   PubMed Web of Science ®Google Scholar
• Sanofi-Aventis. Sanofi-Aventis is complying with the EMEA's recommendation to temporarily suspend the marketing authorization of Acomplia® in obese and overweight patients 2008a, Available at: www.sanofi-aventis.com (accessed October 2008)
   Google Scholar
• Sanofi-Aventis. Sanofi-Aventis to discontinue all clinical trials with rimonabant 2008b, Available at: www.sanofi-aventis.com (accessed December 2008)
   Google Scholar
• Schomacher M, Müller HD, Sommer C, Schwab S, Schäbitz W-R. Endocannabinoids mediate neuroprotrection after transient focal cerebral ischemia. Brain Research 2008; 1240: 213–220
   PubMed Web of Science ®Google Scholar
• Sink KS, McLaughlin PJ, Wood JA, Brown C, Fan P, Vemuri VK, et al. The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 2008; 33: 946–55
   PubMed Web of Science ®Google Scholar
• Solinas M, Tanda G, Justinova Z, Wertheim CE, Yasar S, Piomelli D, et al. The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. Journal of Pharmacology and Experimental Therapeutics 2007; 321: 370–380
   PubMedGoogle Scholar
• Thakur GA, Duclos RI, Jr, Makriyannis A. Natural cannabinoids: Templates for drug discovery. Life Sciences 2005; 78: 454–466
   PubMedGoogle Scholar
• Tsuboi K, Sun YX, Okamoto Y, Araki N, Tonai T, Udea N. Moelcular characterization of N-acetylethanolamide-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. Journal of Biological Chemistry 2005; 12: 11082–11092
   Google Scholar
• University of British Columbia. Cannabinoids in bipolar disorder 2006, Available at: http://www.clinicaltrials.gov/ct2/show/NCT00397605 (accessed November 2008)
   Google Scholar
• University of Cologne. A clinical trial on the antipsychotic properties of cannabidiol 2006, Available at: http://www.clinicaltrials.gov/ct2/show/NCT00309413 (accessed November 2008)
   Google Scholar
• Vemuri VK, Janero DR, Makriyannis A. Pharmacotherapeutic targeting of the endocannabinoid system: Drugs for obesity and the metabolic syndrome. Physiology & Behavior 2008; 93: 671–686
   PubMed Web of Science ®Google Scholar
• Vinod KY, Yalamanchili R, Thanos PK, Vadasz C, Cooper TB, Volkow ND, et al. Genetic and pharmacological manipulations of the CB(1) receptor alter ethanol preference and dependence in ethanol preferring and nonpreferring mice. Synapse 2008; 62: 574–581
   PubMedGoogle Scholar
• Wang T, Collet J-P, Shapiro S, Ware MA. Adverse effects of medicinal cannabinoids: A systematic review. Canadian Medical Association Journal 2008; 178: 1669–1678
   PubMed Web of Science ®Google Scholar
• Woelkart K, Salo-Ahen OMH, Bauer R. CB receptor ligands from plants. Current Topics in Medicinal Chemistry 2008; 8: 173–186
   PubMed Web of Science ®Google Scholar
• Xie XQ, Eissenstat M, Makriyannis A. Common cannabimimetic pharmacophoric requirements between aminoalkyl indoles and classical cannabinoids. Life Sciences 1995; 56: 1963–1970
   PubMed Web of Science ®Google Scholar
• Yale University. Cannabidiol treatement of cognitive dysfunction in schizophrenia 2008, Available at: http://www.clinicaltrials.gov/ct2/show/NCT00588731 (accessed November 2008)
   Google Scholar
• Zvonok N, Pandarinathan L, Williams J, Johnston M, Karageorgos I, Janero DR, et al. Covalent inhibitors of human monoacylglycerol lipase: Ligand-assisted characterization of the catalytic site by mass spectrometry and mutational analysis. Chemistry & Biology 2008; 15: 854–862
   PubMedGoogle Scholar